INTRODUCTION {#S1}
============

Globally, the population is ageing and the World Health Organisation (WHO) predicts that, by 2050, the population aged 60 years or more will double, whilst those aged 80 years or more will number 400 million persons.[@B1] This extension of the lifespan is looked upon as a triumph of medical advances, stemming from access to better treatments as well as a focus on preventive therapies; the use of pharmacotherapy is the key contributor to this.[@B2] Overall, people are using more medication than ever before and, whilst the use of pharmacotherapy has helped people live longer, its use is more complicated and risk-prone in older persons.[@B3] Herein lays the conundrum: pharmacotherapy has facilitated the ageing of the population, however, in the process, has created a population of persons that needs complex polypharmacy to manage their chronic health conditions[@B3], but who also are at-risk of age-associated physiological, functional, and cognitive changes that increase the risk of adverse drug effects.[@B4]

Inappropriate prescribing is often observed in older persons, with reports of both over-treatment[@B5] and under-treatment[@B6], rendering this population vulnerable to adverse clinical outcomes. Often, at the core of this inappropriate prescribing, is decision-making based on chronological age, which has sometimes been referred to as 'ageism' in the use of pharmacotherapy.[@B7] Decision-making based on chronological age has been associated with the under-treatment of acute myocardial infarction[@B6], congestive heart failure[@B8], and atrial fibrillation.[@B9] While there is no doubt that health care professionals possess the skills to make individualised treatment decisions, there are 'hot spots' in practice where decision-making is particularly challenging and which needs some support. The evidence-base specifically highlights the issues of potential age-biases in prescribing, and this is reinforced by emotive discussions taking place in various practice settings identifying the experiences of practitioners and patients alike.[@B10],[@B11] One classic example of this is in atrial fibrillation treatment; patients aged 80 years or more have been found to be five times less likely to receive warfarin compared to those aged less than 80 years.[@B9]

Ageing, an inevitable process, is commonly measured by chronological age and, as a convention, a person aged 65 years or more is often referred to as 'elderly'.[@B12],[@B13] However, the ageing process is not uniform across the population due to differences in genetics, lifestyle, and overall health.[@B14] Thus, chronological age fails to address the heterogeneity observed among the 'elderly', particularly in regard to their pharmacotherapy needs where pharmacokinetic and pharmacodynamic factors necessitate individualisation of regimens.[@B14] However, there are no concrete definitions of 'elderly' that appropriately characterise this patient population; in using the generic terms 'elderly' and 'older persons' (even within this manuscript) there may be variable interpretations of the type of patients that is being referred to, and this is problematic when decisionmaking specifically refers to these. These issues have never been more relevant to clinical practice, given the increasing emphasis on patient-centred care.[@B15] Although, much attention has been paid to developing models and tools which help to individualise therapy (e.g., pharmacometrics[@B16] and physiology-based pharmacokinetic (PBPK) modelling)[@B17], seldom do they account for the diverse range of age-associated factors that influence decision-making in older persons. Moreover, these tools often include age as a determining parameter, with limited ability to tailor therapy to the needs of individual patients according to their unique attributes. For instance, one pharmacometric model defining the relationship between warfarin dose and the international normalised ratio has been based on genetic variations and chronological age only, without consideration of other key patient characteristics (e.g., comorbidities, polypharmacy, cognitive and functional impairments).[@B18] Features of ageing must be appropriately considered within any strategy or tool (including clinical practice guidelines) focused on the individualisation of therapy.

Clinical practice guidelines are 'systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances'.[@B19],[@B20] A systematic review of clinicians' attitudes towards clinical guidelines has found that 70% of the clinicians agree that guidelines are an important source of information. However, 30% criticised these guidelines for their limited applicability to individual patients.[@B21] Thus, it is important to understand what limits the value of these guidelines in actual practice. The aim of this study was to explore how Australian clinical practice guidelines define an 'elderly' patient, to what extent treatment recommendations are made specifically using these terms, and how they consider age-related parameters in the use of pharmacotherapy.

METHODS {#S2}
=======

[Figure 1](#F1){ref-type="fig"} describes the search strategy, data extraction, and search results. A structured review of clinical practice guidelines relating to the use of pharmacotherapy in Australia was undertaken, specifically identifying within each guideline:

Any specific definition of being 'elderly' (quantitative or qualitative definitions)Pharmacokinetic and pharmacodynamic considerations while defining 'elderly'Any age-specific consideration mentioned in the guidelines while making treatment recommendations

![Search strategy, data extraction, and search results](pharmpract-12-489-g001){#F1}

The focus was specifically on clinical conditions mentioned as National Health Priority Areas (NHPA) which include arthritis, asthma, cancer, cardiovascular health, diabetes, dementia, mental health, and obesity, accounting for 72.8% of the total disease and injury burden in Australia.[@B22] In Australia, the development of clinical practice guidelines is primarily overseen by the National Health and Medical Research Council (NHMRC), and/or specific professional organisations and societies specialising in particular areas (e.g. National Heart Foundation, National Stroke Foundation). These clinical practice guidelines are principally directed toward those clinicians and practitioners who are involved in therapeutic decision-making, including prescribers and treatment reviewers.

Guidelines were sourced from an online repository (Clinical Practice Guidelines Portal- an initiative of the NHMRC)[@B23] that was specifically developed to provide ready access to clinical guidelines via a single entry point. A search of the repository was undertaken to identify those guidelines addressing NHPAs, using key words relating to disease/condition names. Other key websites were additionally searched, including the Department of Health and Ageing, the National Heart Foundation of Australia, and NHMRC, as well as online databases, Google Scholar and Medline. Only current guidelines that were available in their entirety were selected for review, excluding those listed as rescinded. In total, 28 guidelines were initially identified, of which 8 were excluded from further review: 5 guidelines were listed as rescinded, and 3 guidelines were in fact only summaries of original guidelines. The remaining 20 guidelines were then reviewed in regard to their consideration of older persons in treatment recommendations.

To qualitatively analyse any descriptors of 'elderly', thematic analysis[@B24] was applied to statements mentioning age related terms such as 'elderly' or "older". To ensure the reliability of the analysis (thematic coding and interpretation), the extracted statements were independently reviewed by both researchers. The themes were independently derived, before a joint discussion to ensure a consensus was reached. Once the core themes had been elicited, their relationship to each other was also explored.

RESULTS {#S3}
=======

Overall, 20 guidelines were reviewed ([Table 1](#T1){ref-type="table"}). Of these, 3 guidelines defined being 'elderly' using chronological age; two guidelines defined 'elderly' by chronological age of 65 years or more and one guideline used the chronological age of 75 years or more. The remaining 17 guidelines did not define 'elderly' by any specific measure.

###### 

Definitions of 'elderly' extracted from clinical guidelines

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Guideline                                     Definition of 'elderly'   Primary developer
  --------------------------------------------- ------------------------- ----------------------------------------------------------------------------------
  Type 2 Diabetes[@B33]                         No                        Diabetes Australia\
                                                                          The Royal Australian College of General Practitioners

  Hypertension[@B32]                            No                        National Heart Foundation of Australia

  Osteoporosis[@B41]                            No                        The Royal Australian College of General Practitioners

  Rheumatoid arthritis[@B31]                    No                        The Royal Australian College of General Practitioners

  Schizophrenia and related disorders[@B57]     No                        The Royal Australian and New Zealand College of Psychiatrists

  Stroke[@B30]                                  Yes (\>65 years)          National Stroke Foundation

  Osteoarthritis[@B29]                          No                        The Royal Australian College of General Practitioners

  Chronic heart failure[@B58]                   No                        National Heart Foundation

  Chronic Obstructive Pulmonary Disease[@B40]   No                        The Thoracic Society of Australia and New Zealand The Australian Lung Foundation

  Absolute cardiovascular disease risk[@B37]    No                        National Vascular Disease Prevention Alliance

  Rheumatic heart disease[@B25]                 No                        Rheumatic Heart Disease Australia

  Breast cancer[@B59]                           No                        iSource National Breast Cancer Centre

  Lung cancer[@B35]                             Yes (\>75 years)          The Australian Cancer Network

  Neuropathic Pain[@B34]                        No                        The Western Australia Therapeutic Advisory Group

  Prostate cancer[@B28]                         No                        The Australian Cancer Network

  Venous leg ulcers^2^'                         No                        The Australian Wound Management Association

  Venous thromboembolism[@B26]                  No                        New South Wales Department of Health

  Overweight and obesity[@B38]                  No                        National Health and Medical Research Council

  Coronary heart disease[@B39]                  No                        National Heart Foundation of Australia

  Major Depressive Disorder[@B36]               Yes (\>65 years)          Australasian Society for Bipolar and Depressive Disorders
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

None of the 20 guidelines purposefully emphasised altered drug pharmacology in older persons to distinguish how the use of the pharmacotherapy might differ in the 'elderly'. However, the guidelines did include statements about specific recommendations, cautionary statements, referral procedures, diagnostic, and emergency care for 'elderly' patients. Five key themes emerged from the qualitative analysis of these statements, outlining how 'elderly' patients were variably considered within practice guidelines. The elicited core themes were explored for their relationship to each other, and the continuum of perceptions about the different levels of understanding about 'ageing' and its application in decision-making was mapped: awareness, acknowledgement, isolation, fear, and evolution ([Figure 1](#F1){ref-type="fig"}). The key themes were:

Age as a surrogate to comorbidity (Awareness)Recognition of issues related to altered drug pharmacology in elderly patients (Acknowledgement, Isolation)Limited evidence base to define recommendations for older patients (Isolation)Old age is associated with restrictions to the use of pharmacotherapy (Isolation, Fear)Features of frailty may underpin treatment recommendations (Evolution)

Age as a surrogate to comorbidity (Awareness) {#S4}
=============================================

In four guidelines, the statements assumed that older persons had multiple co-morbidities and were at-risk of imminent death, almost treating the term 'elderly' as a surrogate for comorbidity and expected 'end of life'. Indeed, several guidelines acknowledged that the risk or prevalence of some diseases was higher in older persons, and therefore there was a need to treat more older persons, although none specifically described the considerations for using the therapies in this patient population.

"In most affluent populations, including much of Australia, ARF (Acute Rheumatic Fever) is now rare, and RHD (Rheumatic Heart Disease) occurs predominantly in the **elderly**".[@B25]As the majority of cancer patients are **elderly,** and as the incidence of VTE (Venous Thromboembolism) increases dramatically in patients aged greater than 55 years, most if not all cancer patients admitted to the hospital will fall into a high risk for subsequent VTE".[@B26]"It is well established that VLUs (Venous Leg Ulcers) occur more often in **older** adults.[@B27]"It is therefore evident that for the foreseeable future we will continue to need to care for a significant number of **older** men with metastatic disease".[@B28]

Recognition of issues related to altered drug pharmacology in elderly patients (Acknowledgement, Isolation) {#S5}
===========================================================================================================

In less than half of the guidelines (n=8), some statements stated the need to adjust drug doses in the elderly to reduce the risk of adverse drug outcomes. The underpinning link to the pharmacology of the therapy may be obvious to most clinicians, although none of the guidelines purposefully described the specific pharmacokinetic and pharmacodynamic considerations.

"GPs should apply caution when using traditional NSAIDs and COX-2 NSAIDs in view of the known side effects, especially in the **elderly,** and those on concomitant medications. Careful monitoring of blood pressure and renal function is indicated in **older** people and others at risk when using these agents".[@B29]"GPs should commence opioids at low starting dose with slow titration dose, particularly in people at increased risk of adverse effects, such as the **elderly,** and closely monitor patients for adverse effects".[@B29]"The known cardiotoxic risk of tricyclic antidepressants (especially in overdose) needs to be balanced by the analgesic benefits for more **elderly** patients with stroke".[@B30]"Addition of GI protective drugs to conventional NSAIDs can significantly reduce complications such as the incidence of GI bleeding and is recommended for RA patients over **65 years of age**".[@B31]"Commence at the lowest possible dose (ACE inhibitors and Angiotensin II receptor antagonists) in **elderly** patients and those taking diuretics".[@B32]"Lowest doses (of Amlodipine and Felodipine) are recommended, particularly in the **elderly**".[@B32]"With sulphonylureas special care needs to be taken, especially in the **elderly,** not to precipitate hypoglycaemia".[@B33]"Starting dose for pregablin is 75 mg bd (25-50 mg in the **elderly** and frail) \[[@B34]\]"Care should always be taken with opioid doses in the **elderly** and in the use of morphine in patients with renal failure" \[[@B35]\]"More caution (with tricyclic antidepressants) is indicated in children and the **elderly** and at higher doses" \[[@B36]\]

Limited evidence base to define recommendations for older patients (Isolation) {#S6}
==============================================================================

The statements from only two guidelines implied or otherwise specifically stated that there was a limited evidence base for the use of pharmacotherapy in older persons, and therefore afforded no practical advice to assist clinical decision-making.

"However not all clinical situations in which their (blood pressure and lipid-lowering agents) use may be considered have been covered by clinical trials, e.g. in the **elderly**".[@B37]"There is insufficient data to evaluate the safety and efficacy of weight loss medication ... in **older** adults".[@B38]

Old age is associated with restrictions to the use of pharmacotherapy (Isolation, Fear) {#S7}
=======================================================================================

A quarter of guidelines (n=5) included statements that indicated that the use of pharmacotherapy should be restricted in older persons, and in some cases a specific chronological age was cited. The rationale for these restrictions was seldom provided, suggestive of potentially age-biased recommendations, some of which related to perceived safety considerations whilst other relating to treatment efficacy.

Recommendations based on perceived safety considerations:

"Prazosin not recommended in the **elderly** or patients with autonomic symptoms or cardiac failure".[@B33]"For patients with ACS (acute coronary syndromes) who are undergoing stenting, Prasugrel 10mg/day can be used as an alternative to Clopidogrel for 12 to 15 months. Avoid prescribing Prasugrel in patients with an increased risk of bleeding: for example, patients with history of smoke/TIA,low body weight (\<60 kg), and **advanced age** (\>75years)".[@B39]

Recommendations relating to efficacy:

"CEA (carotid endarterectomy) for asymptomatic carotid stenosis is more beneficial for men than women and for younger rather than **older** patients".[@B30]"Pneumococcal vaccination is known to be highly effective in preventing invasive bacteraemic pneumococcal pneumonia, but may be less effective in **elderly** or immunosuppressed patient".[@B40]

Unlike the preceding examples highlighting restrictions for the use of therapy in older persons, one statement, in contrast, limited the use of a therapy to 'older' patients only (in preference to younger persons).

"The use of thiazide diuretics as first line therapy (for hypertension) to be limited to **older** patients".[@B32]

Such statements reflect an underestimation of remaining life expectancy in those aged 65 or more, and suggest that it may be appropriate to accept the risks of therapy more so in older persons.

Features of frailty may underpin treatment recommendations (Evolution) {#S8}
======================================================================

Although none of the guidelines specifically discussed or described frailty, four guidelines included statements that suggested a link between frailty and ageing. Some of the recommendations mentioned attributes of old age (such as cognitive impairment, physical status) which may affect medication use/management in the elderly. Broadly speaking, the statements here address the concept of frailty and its application to clinical decision-making.

Recommendations associated with prescribing:

"Less (insulin dose) may be required in **elderly,** active, thin patients and more in the overweight and underactive".[@B33]"Antihypertensive therapy should be initiated with caution in the **very old** or frail (patients with comorbid acute stroke condition)".[@B32]"Calcium intake is often sub-optimal in the **elderly** (especially institutionalised patients)".[@B41]

Generalised statements:

"Many **older** people already have limited mobility, and obesity is likely to aggravate the problem and increase the risk of further functional problem".[@B38]"The effect of excess weight on comorbidities such as Type 2 diabetes also reduce the ability of **older** people to participate in social and physical activities".[@B38]

DISCUSSION {#S9}
==========

A key finding of this study is that contemporary clinical guidelines either did not define 'elderly' by any useful means (85%) and/or otherwise employed chronological age as a definition (15%). While two guidelines defined those aged 65 or beyond as 'elderly', one guideline used 75 years as cut-off for its description of 'elderly'. This variability in setting a 'cut-off' chronological age while defining 'elderly' is another issue which impedes a uniform description of 'elderly'. Similar trends in variably defining 'elderly' have been observed in a range of disease-specific clinical studies, for instance atrial fibrillation.[@B42],[@B43],[@B44]

Any underpinning characterisations of the 'elderly' appear to be very generic, not evidence-based, and potentially biased. Although most guidelines apparently consider the 'elderly' population as a vulnerable population when it comes to using pharmacotherapy, few guidelines are suggestive of the relationship between frailty and ageing, or the relationship between actual physiological changes and the pharmacological handling of a drug. More importantly, none of the guidelines identified that ageing is a heterogeneous process and therefore treatment use must be based on an individual assessment of relevant parameters underpinning the risk versus benefit of therapy.

Individualised pharmacotherapy begins with the realisation that vulnerability to a particular clinical condition, its course, and response to prescribed pharmacotherapy are dependent on multiple factors including ageing, gender, genetics, lifestyle, and social-cultural aspects.[@B45] Based on these factors, differing significantly from person to person, patients can be stratified for treatment recommendations, supporting a patient-centre treatment approach. Any treatment recommendation presented by clinical guidelines that regard the 'elderly to be a homogenous group of people may limit the clinical benefits of therapy.[@B46] For instance, one of the guidelines reviewed in this study limited the use of thiazide diuretics (associated with elevated risk of diabetes) as first line therapy to older people only.[@B32]

Few studies have systematically addressed the issue of chronological age-based descriptions of 'elderly' in clinical settings; however a few have argued the need to review definition. Orimo *et al*.[@B13] considered that, given the improving health status and functional independence in older persons, changing cut-off age from 65 years to 75 years to define 'elderly'. Similarly, improvements in health, cognition, and functional abilities of those aged 70 or more were observed in a longitudinal study supporting the need to change the cut-off age for defining 'elderly'.[@B47] However, some researchers have recommended other options for defining being 'old', for example, the use of biological age.[@B48],[@B49] In the context of clinical guidelines, it is important to base treatment recommendations on an individual assessment of those specific factors known to affect the use of a particular medication and avoid using generic age-based approaches. Other guidelines (not relevant to pharmacotherapy) also highlight the requirement of such an approach. [@B50]

Clinical practice guidelines are important tools, but are frequently criticised for their insensitivity towards the needs of, and/or their limited applicability to, the older patient population.[@B51] The findings of this study support this, in that the reviewed guidelines failed to present a comprehensive or practical definition of 'elderly' either in qualitative or quantitative terms. Chronological age-based definitions of 'elderly', as presented in three guidelines, provide no insight about the actual health status and unique needs of a patient. Thus, such recommendations have limited ability to assist health professionals in decision-making. A patient's unique characteristics such as: altered drug handling, physical/functional and cognitive function, extent of comorbidity, polypharmacy, social situation, and quality of life, should be considered in clinical guidelines. Current guidelines only allude to these issues at a surface-level, without adequate definition and support, and a few continue to use relatively arbitrary definitions of ageing based on chronological age.

As the continuum of perception of 'ageing' ranges from 'awareness' to 'evolution', there is an increasing focus on to assist clinicians in prescribing for the 'elderly'. Tools such as STOPP and START criteria[@B52], BEERS criteria[@B53], as well as pharmacist-led review services[@B54],[@B55] can assist in rationalising therapy. The concept of frailty is also emerging as a more reliable predictor of the heterogeneity that exists in this potentially vulnerable population.[@B49] The frailty index might be operationalised to determine the biological age of a patient[@B48], providing a longitudinal measure of health status in an individual which can subsequently be applied to guide decision-making.[@B14]

The inclusion of only Australian guidelines is a potential limitation of this study. However, although Australian guidelines have often (historically) been derived from international ones, this is less common in contemporary practice.[@B56] Whilst it is not expected that practice and guidelines differ substantially in Australia compared to comparable international settings, further research in this area is needed to confirm the full scope of the issues.

This study highlights the existing gaps in understanding of 'old' age and the 'elderly' underpinning some potential age-biases in medication prescribing, and highlighting the limited extent to which current clinical practice guidelines address this. Although clinicians' abilities are not in question here, it is apparent that clinical guidelines often do not provide enough guidance on how to translate recommendations to individual patients, particularly older persons. More attention needs to be paid to this within guidelines given that no other factor displays more inter-patient variability in its presentation than 'age'.

CONCLUSIONS {#S10}
===========

Clinical practice guidelines currently do not adequately define 'elderly' persons and provide limited guidance on how to apply treatment recommendations to older persons. The representation of 'elderly' in guidelines needs to be less based on chronological age or generic definitions focusing more on establishing a direct link between an individual patient's characteristics and the pharmacology of their prescribed medication. Clinical guidelines that do not offer any practical descriptions of the features of ageing that are specifically related to the use of pharmacotherapy, or how to assess these in individual patients, render decision-making challenging.
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